Fundraising FoxNexgenia
Seattle, US · Founded 2011 · Delaware corporation · 3 known investors
Find your way into Nexgenia
Sign up to find every way you can get introduced to Nexgenia
- Your email: who you already know at Nexgenia, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nexgenia team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays. The company's technology enables faster and more efficient separation and analysis of cells and molecules through reversible phase transitions triggered by temperature, pH, or salt changes.
Founders & leadership
RM
Ron MyersExecutive
Board
SG
Steven GillisBoard directorManaging Director, ARCH Venture Partners at The W Fund
CP
Charles P. WaiteBoard director
MS
Martin SimonettiBoard director
SP
Stewart ParkerBoard director
DU
David UrdalBoard director
Investors · 3
The W Fundlisted by The W FundSeattle · $500K
How we know: The W Fund's portfolio page · Not right? Tell us
Alliance of AngelsreportedSeattle
How we know: funding news · allianceofangels.com · Not right? Tell us
WRF CapitalreportedSeattle · $100K – $2M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.1M disclosed across 4 of 5 rounds · 2014–2018
▶$119.1KraisedMay 2018 · 14 investors · BiotechnologyRule 506(b)
▶$119.1KraisedMay 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven GillisDirector
- Stewart ParkerDirector
- Ron MyersExecutive Officer, Director
- David UrdalDirector
- Martin SimonettiDirector
- Charles P. WaiteDirector
- Offering amount
- $250K
- Amount sold
- $119.1K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9KofferedApr 2017 · 1 investors · BiotechnologyRule 506(b)
▶$1.9KofferedApr 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron MyersExecutive Officer, Director
- Charles P. WaiteDirector
- David UrdalDirector
- Steven GillisDirector
- Stewart ParkerDirector
- Martin SimonettiDirector
- Offering amount
- $1.9K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedAug 2016 · 15 investors · BiotechnologyRule 506(b)
▶$1.9MraisedAug 2016 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin SimonettiDirector
- Charles P. WaiteDirector
- David UrdalDirector
- Stewart ParkerDirector
- Ron MyersExecutive Officer, Director
- Steven GillisDirector
- Offering amount
- $2M
- Amount sold
- $1.9M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJun 2015 · 9 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJun 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin SimonettiDirector
- Stewart ParkerDirector
- David UrdalDirector
- Ron MyersExecutive Officer, Director
- Steven GillisDirector
- Charles P. WaiteDirector
- Offering amount
- $3.5M
- Amount sold
- $1.6M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$500KraisedOct 2014 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedOct 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stewart ParkerDirector
- David UrdalDirector
- Ron MyersExecutive Officer, Director
- Martin SimonettiDirector
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Mission BioCapital Platinum Program Holdings LLCMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.
ComparablyCrew32 maintains a database of compensation and workplace culture information that companies can compare against industry benchmarks. Its data is segmented by factors such as gender, experience level, region and company size, and includes startup salary figures indexed to the amount of venture funding a company has raised.
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
WugenAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
TellBioTellBio is a biotechnology company founded by leading cancer researchers and clinicians from Harvard Medical School and Massachusetts General Hospital. The company focuses on oncology research and development, leveraging circulating tumor cell (CTC) technology and biomedical engineering.
ImmunovantImmunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
Companies working in the same space as Nexgenia.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $232.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $196.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Nexgenia do?
- Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays. The company's technology enables faster and more efficient separation and analysis of cells and molecules through reversible phase transitions triggered by temperature, pH, or salt changes.
- Who are Nexgenia's investors?
- Nexgenia's investors include The W Fund, Alliance of Angels, WRF Capital.
- How much funding has Nexgenia raised?
- Nexgenia has disclosed $4.1M raised across 4 of its 5 known rounds.
- Where is Nexgenia headquartered?
- Nexgenia is headquartered in Seattle, US.